Heterogenous distribution of PD-1+CD39+CD8+ T cell in TME defined its
immunotherapeutic biomarker in lung cancer
CD8+ T cells in tumors are heterogenous and exist in multiple
differentiation states. Evidence has proposed CD39 as a marker of
exhausted and tumor-reactive CD8+ T cells. Here, we analyzed a subset of
tumor-infiltrating CD8+ T cells based on the expression of the
immunosuppressive ATP ectonucleotidase CD39 and PD-1.
Neoplasm-superficial biopsy and intratumoral EBUS-TBNA were used to
assess the peripheral and central tumor microenvironment, respectively.
CD39+CD8+ T cells dominantly accumulated in the peritumoral compartment
of larger tumors and exhibited an exhausted phenotype compatible with
PD-1 expression. Compared with CD39+CD8+ T cells, PD-1+CD39+CD8+ T cells
are better biomarkers for predicting responses to anti-PD-1 therapy.
Collectively, heterogenous distribution may be critical to elicit CD39
expression in lung cancer associated CD8+ T cells. Increased
PD-1+CD39+CD8+ T cell levels within the peripheral TME can act as a
candidate biomarker for lung cancer immunotherapy.